Health Care Down as Selling Broadens — Health Care Roundup
Health-care companies fell as traders dumped stocks of all description ahead of a litmus test for the artificial-intelligence boom.
The SPDR Select Sector Health Care exchange-traded fund, which tracks the health-care industrial group of the S&P 500, has held up better than most during the recent AI scare, and is up by more than 5% over the last month, thanks to a strong earnings season and the evergreen nature of the business.
Eli Lilly gave back some of its recent gains after reports the obesity drug maker was named this week by a cyber extortion group threatening to leak data tied to over 1 million patients. Lilly reportedly purchases services from a compromised third-party vendor.
Swiss drug maker Roche received Food and Drug Administration approval for a new oral breast-cancer therapy that the drugmaker has touted as a potential blockbuster.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
November 17, 2026 17:47 ET (22:47 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?

